期刊文献+

经蝶显微手术治疗男性泌乳素腺瘤及对性功能的影响 被引量:1

Transsphenoidal microsurgical treatment of male prolactinoma and sexual disfuction
原文传递
导出
摘要 目的探讨经蝶窦显微手术对男性泌乳素腺瘤患者的治疗效果和对性功能的影响。方法对23例男性泌乳素腺瘤患者进行了部分回顾性和部分前瞻性研究,其中10例术前接受溴隐亭治疗1~14个月(平均7.3个月),剂量在7.5~15.0mg/d。9例完成国际勃起功能评分(II EF-15)问卷调查。结果术前服用溴隐亭治疗者手术治愈缓解8/10例,单纯手术治疗者治愈缓解4/13例,两者疗效差异有统计学意义(X^2=5.490,P=0.036)。9例基于ⅡEF-15问卷评分,术后较术前性功能改善(配对样本t检验,P<0.05)。结论经蝶显微手术可改善患者的性功能,术前服用多巴胺激动剂有可能提高手术治愈率。 Objective To explore the features of transsphenoidal microsurgical treatment of male prolactinoma and to evaluate the sexual function before and after transsphenoidal microsurgery. Methods A series of 23 cases male prolactinoma were analysed combined with retrospective and prospective study. 9 casese with sexual disfunction had finished the International Index of Erectile Function with 15-item questionnnaire ( Ⅱ EF-15 ) before and after the surgery. Results 8/10 cases treated with dopaminergic agonist combined with surgery achieved complete remission, while only 4/13 cases achieved complete remission with surgery only(x^2 =5.490,P =0. 036). Accoding to Ⅱ EF-15 ,sexual function improved after surgery in 9 cases( pairedsample) t test,P 〈0. 05). Conclusion Transsphenoidal microsurgical treatment of prolactinoma may improve the male sexual functions, Dopaminergic agonist combined transsphenoidal microsurgery may achieve a better outcome.
出处 《中华显微外科杂志》 CSCD 北大核心 2006年第6期406-408,共3页 Chinese Journal of Microsurgery
关键词 泌乳素腺瘤 经蝶入路 显微外科手术 男性 Prolactinoma Transsphenoidal approach Microsurgical operation Male
  • 相关文献

参考文献7

  • 1骆纯,卢亦成,孙克华,丁学华,胡国汉,楼美清,陈菊样,吴小军,姚志强.男性垂体泌乳素腺瘤的显微手术治疗[J].中华显微外科杂志,2005,28(2):109-111. 被引量:3
  • 2徐剑,金自孟,邓洁英,吴勤勇,史轶蘩.男性垂体催乳素大腺瘤103例临床分析[J].中华内科杂志,2005,44(5):356-359. 被引量:12
  • 3王任直,任祖渊,苏长保,张雪峰,杨义,马文斌,连伟.男性垂体泌乳素腺瘤的诊断和治疗[J].中华神经外科杂志,2000,16(3):139-142. 被引量:19
  • 4Raymond CR, Alan R, Gorm W, et al. The International Index of Erectile Function (Ⅱ EF) :a multidimensional scale for assessment of erectile disfunction. Urology, 1997,49:822 - 830.
  • 5Ramot Y, Rapoport M J, Hagag P, et al. A study of the clinical differences between women and men with hyperprolactinemia.Gynecol Endocrinol, 1996,10:397 - 400.
  • 6Nomiks P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol, 2001,16 : 139-142.
  • 7Gokalp HZ, Deda H, Ataar A, et al. The meurosurgical management of prolactinomas. J Neurosurg Sci, 2000,44 : 128 -132.

二级参考文献19

  • 1Wilson CB. A decade of pituitary microsurgery:the Herbert Olivercrona lecture. J Neurosurg, 1984,61:814 - 855.
  • 2Ramot Y, Rapoport M J, Hagag P, et al. A study of the clinical differences between women and mean with hyperprolactinemial. Gynecol Endocrinol, 1996,10:397 - 400.
  • 3Nishioka H, Haraoka K, Akada K, et al. Center-related differences in prolactin secretion in pituitary prolactinoma. Neuroradiology ,2002,95: 258 - 266.
  • 4Ozgen T, Oruckaptan HH, Ozcan OE, et al. Prolactin secreting pituitary adenolas: analysis of 429 surgically treated poatients,effect of adjuvant treatment modalities and review of the literature. Act Neurochir (Wien) , 1999,141:1287 - 1294.
  • 5史轶蘩.生长激素分泌瘤[A].见:史轶蘩 主编.协和内分泌和代谢学[C].北京:科学出版社,1999.674-699.
  • 6Tyrrell JB, Lamborn KR, Hannegan LT, et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery, 1999,44:254-261.
  • 7Pinzone JJ, Katznelson L, Danila DC, et al. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab, 2000,85:3053-3057.
  • 8Ozgen T, Oruckaptan HH, Ozcan OE, et al. Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochir, 1999, 141:1287-1294.
  • 9Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab, 1997,82:996-1000.
  • 10Passos VQ, Souza JJ, Musolino NR, et al. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab, 2002,87:3578-3582.

共引文献30

同被引文献9

  • 1徐剑,金自孟,邓洁英,吴勤勇,史轶蘩.男性垂体催乳素大腺瘤103例临床分析[J].中华内科杂志,2005,44(5):356-359. 被引量:12
  • 2Colao A, Savastano S. Medical treatment of prolaetinomas. Endocrinol, 2011 ;7(5) :267-278.
  • 3Shlomo M, Felipe F, Casanueva AR, et al. Diagnosis and treatment of hyperprolaetinemia: an endocrine society clinical practice guideline. Clin Endocrinol, 2011 ; 96 (2) : 273-288.
  • 4Acquati S, Pizzocaro A, Tomei G, et al. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci, 2001; 45 (2):65-69.
  • 5Doknic M, Pekie S, Zarkovic M, etal. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol, 2002 ; 147 (1) : 77-84.
  • 6Patel SS, Bamigboye V. Hyperprolactinaemia. J Obstet Gynaecol,2007,27(5) :455-459.
  • 7Rama W, Anil B, Pinaki D, et al. Recovery pattern of hypot halamo-pit uitary-t esticular axis in patients with macroprolaetinomas after treatment with cabergoline. Indian JMed Res,2011,134(3):314-319.
  • 8Kawabata Y, Ueno Y, Horikawa F, et al. Remarkable effects of cabergoline in a patient with huge prolactimoma resistant to high-dose bromocriptine: case report. Surg Neurol, 2008; 69 (1):85-88.
  • 9卢旺盛,岳志健,周晓平,魏梁峰,洪波,王文仲,林富禄.溴隐亭在泌乳素腺瘤治疗中的应用[J].第二军医大学学报,2003,24(8):914-915. 被引量:9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部